Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968930 | 1.00 | APP (0.47) | APPLMNARPS6KA3TTRAMY1A | |
| SCHEMBL16245222 | 0.84 | PKM (0.52) | LMNAPTGS2CA12CA1CA2 | |
| SCHEMBL24110788 | 0.78 | ALOX5 (0.57) | APPLMNARPS6KA3TTRAMY1A | |
| SCHEMBL27280320 | 0.78 | TTR (0.64) | APPLMNARPS6KA3TTRAMY1A | |
| SCHEMBL7195739 | 0.77 | ABL1 (0.50) | APPLMNARPS6KA3TTRAMY1A | |
| SCHEMBL12584694 | 0.77 | ERN1 (0.53) | APPLMNARPS6KA3TTRAMY1A | |
| SCHEMBL5959273 | 0.75 | ALOX5 (0.64) | LMNAPTGS2CA12CA1CA2 | |
| SCHEMBL16345333 | 0.75 | ERN1 (0.55) | APPLMNARPS6KA3TTRAMY1A | |
| SCHEMBL24407648 | 0.75 | APP (0.47) | APPLMNARPS6KA3TTRAMY1A | |
| SCHEMBL5959270 | 0.75 | ALOX5 (0.64) | LMNAPTGS2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951215-A4 | HYDRAZONE DERIVATIVES AND USES THEREOF | REDPOINT BIO CORP (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1951215-A2 | HYDRAZONE DERIVATIVES AND USES THEREOF | Redpoint Bio Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
| WO-2007056159-A2 | HYDRAZONE DERIVATIVES AND USES THEREOF | REDPOINT BIO CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-0748219-B8 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-0748219-A4 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0748219-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | Sugen, Inc. (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995021613-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | APP 2815/4885LMNA 4648/4885RPS6KA3 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.